注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶？ 登入
安進公司 (AMGN)
NASDAQ
| 代號 | 交易所 | 貨幣 | ||
|---|---|---|---|---|
| AMGN | NASDAQ | USD | 即時 | |
| AMGN | BIVA | MXN | 延遲 | |
| AMGN | 墨西哥 | MXN | 延遲 | |
| AAMGN | 米蘭 | EUR | 即時 | |
| AMGN | TradeGate | EUR | 延遲 | |
| AMGN | 法蘭克福 | EUR | 延遲 | |
| AMGN | Xetra | EUR | 延遲 | |
| AMGN | 布宜諾斯艾利斯 | ARS | 延遲 | |
| AMGN34 | B3 | BRL | 延遲 | |
| 4332 | 香港 | HKD | 延遲 | |
| AMGN | 維也納 | EUR | 即時 |
從投資組合中新增/移除
新增至觀察名單
安進
268.93
+6.18
+2.35%
安進公司公司檔案
在此獲得安進公司的詳細檔案，包括公司業務、主要管理層介紹、員主資料和位址聯繫方式。
安進公司是一家生物技術公司。該公司探索、開發、製造及銷售人類治療藥品。該公司通過人類治療藥品業務運營。該公司銷售的藥品包括：Neulasta（pegfilgrastim），Aranesp（darbepoetin alfa）及EPOGEN（epoetin alfa）等促紅細胞生成劑，Sensipar/Mimpara（cinacalcet），XGEVA（denosumab），Prolia（denosumab），NEUPOGEN（filgrastim），和Vectibix（panitumumab）、Nplate（romiplostim）及Corlanor（ivabradine）等。該公司專注於研髮用於治療腫瘤及血液病、心血管病、炎症、骨骼病、腎髒病及神經疾病等嚴重疾病的人類藥物。該公司研發的處於第III階段的產品包括用於發作性偏頭痛的Erenumab，骨髓增生異常綜合徵的Aranesp，急性淋巴細胞白血病的BLINCYTO和轉移性黑色素瘤的IMLYGIC。
聯絡資訊
地址
One Amgen Center Drive
Thousand Oaks, 91320-1799
United States
Thousand Oaks, 91320-1799
United States
電話
805 447 1000
傳真
805 447 1010
主要管理層
| 名稱 | 年齡 | 成立於 | 主旨 |
|---|---|---|---|
| Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
| Robert A. Eckert | 69 | 2012 | Lead Independent Director |
| Greg C. Garland | 66 | 2013 | Independent Director |
| Tyler E. Jacks | 62 | 2012 | Independent Director |
| Brian J. Druker | 68 | 2018 | Independent Director |
| Ellen J. Kullman | 67 | 2016 | Independent Director |
| David Baltimore | 85 | 1999 | Co-Chair of Scientific Advisory Board |
| Wanda M. Austin | 69 | 2017 | Independent Director |
| Amy E. Miles | 56 | 2020 | Independent Director |
| S. Omar Ishrak | 67 | 2021 | Independent Director |
| Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
| Ronald D. Sugar | 74 | 2010 | Independent Director |
| R. Sanders Williams | 74 | 2014 | Independent Director |
| Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
| Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
| Charles M. Holley | 66 | 2017 | Independent Director |
| Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
| S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
| Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
| Michael V. Drake | 72 | 2022 | Independent Director |
| Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
| Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
| Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
| Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
| Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| Robert Tjian | 74 | - | Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies |
| Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
| Frank P. McCormick | 73 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| Ronald M. Evans | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| George Georgiou | 64 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| Elizabeth McNally | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| Drew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
| Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
| Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
| Antoni Ribas | - | - | Member of Scientific Advisory Board of Oncology |
| Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
| David J. Anderson | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| Peter Libby | 76 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
| Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
| Charles Elliott Sigal | 72 | - | Co-Chair of the Scientific Advisory Board |
| Thomas Quertermous | 72 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
在留言中加插圖表
確認封鎖
你確定要封鎖 %USER_NAME%？
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖，必須等候 48 小時後才可再次封鎖。
舉報此評論
我覺得這個評論是:
評論被加標記
謝謝！
您的報告已被發送到我們的版主審核